Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Acumen Pharmaceuticals Inc (NQ: ABOS )

3.385 -0.085 (-2.45%)
Streaming Delayed Price Updated: 10:32 AM EDT, Apr 18, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 40,475
Open 3.430
Bid (Size) 3.380 (6)
Ask (Size) 3.390 (4)
Prev. Close 3.470
Today's Range 3.375 - 3.480
52wk Range 1.810 - 11.31
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Acumen Pharmaceuticals Presents First Comprehensive Clinical and Biomarker Data for Sabirnetug (ACU193) at American Academy of Neurology 2024 Annual Meeting
From Acumen Pharmaceuticals, Inc.
Via GlobeNewswire
Acumen Pharmaceuticals Collaborates with Lonza to Advance Sabirnetug for the Treatment of Alzheimer’s Disease
From Acumen Pharmaceuticals, Inc.
Via GlobeNewswire

Performance

YTD
-19.98%
-19.98%
1 Month
-14.95%
-14.95%
3 Month
-9.73%
-9.73%
6 Month
-5.31%
-5.31%
1 Year
-5.71%
-5.71%

More News

Read More
Acumen Pharmaceuticals's Earnings: A Preview
Via Benzinga
Acumen Pharmaceuticals's Earnings Outlook
Via Benzinga
ABOS Stock Earnings: Acumen Pharmaceuticals Misses EPS for Q4 2023
Via InvestorPlace
Acumen Pharmaceuticals Reports Financial Results for the Year Ended December 31, 2023 and Business Highlights
From Acumen Pharmaceuticals, Inc.
Via GlobeNewswire
Acumen Pharmaceuticals to Present Deeper Insights, Including Fluid Biomarker Data for Sabirnetug (ACU193), During Emerging Science Session at the American Academy of Neurology Annual Meeting
From Acumen Pharmaceuticals, Inc.
Via GlobeNewswire
Acumen Pharmaceuticals to Report Fourth Quarter and Year-End 2023 Financial Results on March 26, 2024
From Acumen Pharmaceuticals, Inc.
Via GlobeNewswire
Earnings Scheduled For March 26, 2024
Via Benzinga
Acumen Pharmaceuticals to Participate in the Stifel 2024 CNS Days
From Acumen Pharmaceuticals, Inc.
Via GlobeNewswire
Acumen Pharmaceuticals Presents Sabirnetug (ACU193) Fluid Biomarker and Target Engagement Analyses from Phase 1 INTERCEPT-AD Study in Early Alzheimer’s at the AD/PD™ 2024 Annual Meeting
From Acumen Pharmaceuticals, Inc.
Via GlobeNewswire
Acumen Pharmaceuticals to Present Sabirnetug (ACU193) Fluid Biomarker and Target Engagement Analyses from Phase 1 INTERCEPT-AD Study in Early Alzheimer’s at the AD/PD™ 2024 Annual Meeting
From Acumen Pharmaceuticals, Inc.
Via GlobeNewswire
Acumen Pharmaceuticals Appoints Dr. James Doherty as President and Chief Development Officer
From Acumen Pharmaceuticals, Inc.
Via GlobeNewswire
Buy Alert: 3 Healthcare Stocks Sitting in the Sweet Spot
Via InvestorPlace
3 Healthcare Stocks to Buy as the Sector Benefits from the Aging Boom
Via InvestorPlace
Acumen Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference
From Acumen Pharmaceuticals, Inc.
Via GlobeNewswire
Are You A Trader Or Investor: Biotech Momentum Is Picking Up
Via Talk Markets
Topics ETFs
Quest For Alzheimer's Cure: Big Biotech Breakthroughs, But The Race Is Just Beginning
Via Investor's Business Daily
Acumen Pharmaceuticals Reports Third Quarter 2023 Financial Results and Business Highlights
From Acumen Pharmaceuticals, Inc.
Via GlobeNewswire
Acumen Pharmaceuticals Secures $50.0 Million Credit Facility with K2 HealthVentures
From Acumen Pharmaceuticals, Inc.
Via GlobeNewswire
Earnings Scheduled For November 13, 2023
Via Benzinga
Under the Microscope: 3 Biotech Stocks Pioneering Tomorrow’s Cures
Via InvestorPlace
3 Promising Biotech Stocks Flying Under the Radar
Via InvestorPlace
Acumen Pharmaceuticals to Participate in the Stifel Healthcare Conference
From Acumen Pharmaceuticals, Inc.
Via GlobeNewswire
Acumen Pharmaceuticals to Report Third Quarter Financial Results on November 13, 2023
From Acumen Pharmaceuticals, Inc.
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.